EP4051278
COMBINATION OF A PD-1 ANTAGONIST, A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR AND A CBP/BETA-CATENIN INHIBITOR FOR TREATING CANCER
Status:
EP einkaleyfi: Þýðing ekki lögð innEP appl. date:
28.10.2020EP published:
17.12.2025EP application number:
20811814.1
EPO information:
European Patent Register
Max expiry date:
27.10.2040
Title in English:
COMBINATION OF A PD-1 ANTAGONIST, A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR AND A CBP/BETA-CATENIN INHIBITOR FOR TREATING CANCERLanguage of the patent:
English
Timeline
Today
28.10.2020EP application
17.12.2025EP Publication
Owner
Name:
Eisai R&D Management Co., Ltd.Address:
6-10 Koishikawa, 4-Chome Bunkyo-Ku, Tokyo 112-8088, JP
Name:
Merck Sharp & Dohme LLCAddress:
126 East Lincoln Avenue, Rahway, New Jersey 07065, US
Name:
MSD International GmbHAddress:
Weystrasse 20, 6006 Luzern, CH
Inventor
Name:
OZAWA, YoichiAddress:
Tsukuba-shi, Ibaraki 300-2635, JP
Name:
FUNAHASHI, YasuhiroAddress:
Tsukuba-shi, Ibaraki 300-2635, JP
Name:
KATO, YuAddress:
Tsukuba-shi, Ibaraki 300-2635, JP
Priority
Number:
201962927334 PDate:
29.10.2019Country:
US
Number:
201962927576 PDate:
29.10.2019Country:
US
Classification
Categories:
A61K 31/47, A61K 31/53, A61K 39/395, A61K 45/06, A61P 35/00